Alpha-1-antitrypsin (AAT), a serine protease inhibitor (serpin), is increasingly recognized to inhibit SARS-CoV-2 infection and counter many of the pathogenic mechanisms of COVID-19. Herein, we reviewed the epidemiologic evidence, the molecular mechanisms, and the clinical evidence that support this paradigm. As background to our discussion, we first examined the basic mechanism of SARS-CoV-2 infection and contend that despite the availability of vaccines and anti-viral agents, COVID-19 remains problematic due to viral evolution. We next underscored that measures to prevent severe COVID-19 currently exists but teeters on a balance and that current treatment for severe COVID-19 remains grossly suboptimal. We then reviewed the epidemiologic and clinical evidence that AAT deficiency increases risk of COVID-19 infection and of more severe disease, and the experimental evidence that AAT inhibits cell surface transmembrane protease 2 (TMPRSS2) — a host serine protease required for SARS-CoV-2 entry into cells — and that this inhibition may be augmented by heparin. We also elaborated on the panoply of other activities of AAT (and heparin) that could mitigate severity of COVID-19. Finally, we evaluated the available clinical evidence for AAT treatment of COVID-19.

There is burgeoning evidence that alpha-1-antitrypsin (AAT), the most abundant endogenous serine protease inhibitor (serpin), inhibits SARS-CoV-2 infection and mitigates many of the pathogenic mechanisms of COVID-19. Herein, we review the literature and mechanisms by which AAT antagonizes SARS-CoV-2 and COVID-19.

Upon binding of the spike protein of SARS-CoV-2 to its receptor angiotensin converting enzyme 2 (ACE2) on the cell membranes, the spike protein is sequentially cleaved by the cell surface serine proteases furin at the S1/S2 site and transmembrane protease 2 (TMPRSS2) at the S2’ site [1,2]. Moreover, neutrophil elastase, the canonical target of AAT, also cleaves near the S1/S2 site for the SARS-CoV-2 variant with the D614G mutation in the spike protein [3]. These modifications of the spike protein enable fusion of the viral envelope with the cell plasma membrane.

SARS-CoV-2, the cause of COVID-19, is the third beta-coronavirus and second sarbecovirus to emerge in humans in this century. It is likely that additional coronaviruses will jump the species barrier, potentially leading to new pandemics. Hence, despite the availability of efficacious COVID-19 vaccines, future SARS-related strains and other coronaviruses are likely to remain problematic because: (i) vaccine-refusal within a segment of the population, estimated to occur in 25–30% of the U.S. population per 2021 Gallup Poll and Monmouth University Polling Institute as well as the 4% vaccination rate in resource-poor countries, seedbeds for development of new SARS-CoV-2 variants; (ii) breakthrough cases even in those who have been vaccinated, especially in immunocompromised individuals [4–9]; (iii) fatigue in public health measures; (iv) anti-viral agents Paxlovid (nirmatrelvir + ritonavir) and molnupiravir were largely studied in the context of earlier SARS-CoV-2 strains with more recent occurrence of breakthrough symptoms and viral replication [10,11]; and (v) evolution of new SARS-CoV-2 strains such as the now dominant omicron strains (e.g. BQ.1, BQ.1.1, and XBB.1.5), which are much more transmissible, more immune evasive, less responsive to vaccines/boosters with protection that declines more rapidly, and/or increased or complete resistance to existing monoclonal antibodies [12–21]. Even as recently as September 2022, when the number of patients hospitalized for COVID-19 were declining, 500–1000 individuals still die each day (182 000–365 000 per year) from COVID-19 in the U.S. In contrast, 12 000–52 000 people die from influenza each year in the U.S. for the last 10 years before COVID-19.

Pneumonia/acute lung injury with refractory hypoxemia and septic shock due to a hyperinflammatory response — due largely to increases in inflammatory cells recruited and activated by interleukin-1 (IL-1), IL-6, IL-8, IL-17, and tumor necrosis factor (TNF) — are the most common causes of COVID-19 deaths [22–26]. Severe COVID-19 is also associated with CD4+ and CD8+ T cell lymphopenia and decreased interferon-gamma (IFNγ)-positive CD4+ T cells [27]. The current treatment for severe COVID-19 is largely supportive care combined with the glucocorticoid dexamethasone, which reduced mortality by 2.9% in those receiving supplemental oxygen only and by 12.1% in those requiring mechanical ventilation [28]. Remdesivir is also used for hospitalized patients [29] although its efficacy is controversial [30,31]. Anakinra (IL-1 receptor antagonist, IL-1Ra) has been evaluated for treatment of severe COVID-19 with no or marginal success [32–36].

Antagonists to IL-6 and IL-6 receptor (IL-6R) have shown either negative results or benefit in some patients recalcitrant to dexamethasone [37]. Several concerns with the use of antagonists to IL-6 or IL-6R are that IL-6 helps induce antibody production and activates T cells against infectious agents [22,38]. The FDA has also issued a Black Box warning for the anti-inflammatory Janus kinase 1 inhibitors (baricitinib, tofacitinib, upadacitinib) due to risks of serious cardiac events and cancer.

AAT is the third most abundant protein in plasma and the most prevalent serpin in the body. As an acute phase protein, AAT levels increase three- to five-fold with systemic infection or inflammation, underscoring its important homeostatic function [39,40]. Persons with a normal SERPINA1 gene are designated as protease inhibitor MM (PiMM). Two of the most common abnormal AAT alleles are Z-AAT (rs28929474) and S-AAT (rs17580), with the PiZZ, PiSZ, and some PiMZ genotypes resulting in severe or relative AAT deficiency. Some AAT alleles (F and I) encode a dysfunctional AAT protein but with normal circulating levels.

It has been estimated that approximately 100 000 individuals in the U.S. have severe AAT deficiency, with <10% currently identified [41]. However, this assessment is likely to be underestimated based on the calculation that if there are 13 million subjects with chronic obstructive pulmonary disease (COPD) in the U.S. — and that AAT deficiency (mostly PiZZ) is a well-established risk factor for COPD and PiZZ comprises 1–3% of all COPD cases [42] with both lower and higher prevalence reported based on the cohort defined [43] — then 130 000–390 000 with known COPD are predicted to be AAT deficient (PiZZ). The number of AAT deficient individuals in the U.S. population is likely to be even more as some patients with AAT deficiency have not developed COPD (e.g. children), COPD has yet to be detected in them, or have undiagnosed AAT deficiency-associated liver disease. Even in the absence of frank AAT deficiency, the AAT response to a systemic infection may be inadequate as has been shown for hospitalized COVID-19 patients [44,45] and among millions with certain heterozygous AAT mutations (PiMZ) [39]. Furthermore, oxidation of methionine 351 and/or 358 of even normal AAT may cause loss of its serpin activity [46]. Oxidation may also induce AAT polymerization [47,48]. Because COVID-19 is associated with increased oxidative stress [49], AAT may be rendered ineffective even with increased levels. Indeed, the concept of ‘relative AAT deficiency’ has been raised wherein external stressors such as oxidative stress, smoke exposure, high glucose levels, and bacterial proteases inactivates normal AAT [50].

COVID-19 cases were increased in parts of Italy with greater prevalence of AAT deficiency [51]. AAT-deficient subjects were also found to be 8.8-fold more likely to have symptomatic COVID-19 than the general population [52]. Shapira et al. [53] found a significant direct correlation between the frequency of the PiZ and PiS alleles with COVID-19 death rates in 67 countries. Yoshikura [54] also reported a robust correlation between the Pi*Z variant and the number of COVID-19 cases (correlation coefficient (CC) = 0.8584) and deaths (CC = 0.8713) in 68 countries. Both Europeans and Latinos have relatively higher rates of PiZZ, PiSZ, and PiMZ, estimated to be ∼12%, and are also the predominant ethnic groups in countries having the highest COVID-19 cases and deaths [55–58]. Furthermore, evidence implicates AAT deficiency itself — and not its pulmonary sequelae of emphysema or bronchiectasis – as a major risk factor for SARS-CoV-2 infection [57]. Hospitalized patients with severe COVID-19 had significantly lower plasma AAT levels than those admitted for non-COVID-19 pneumonia [59]. In a multi-center study of over 2000 patients with COVID-19, possessing the Pi*Z allele and/or plasma AAT level <116 mg/dl were highly associated with severe COVID-19 compared with non-severe disease [60]. In 105 subjects with AAT deficiency and COVID-19 infections in 10 European countries, poor outcome was more likely with PiZZ genotype than PiSZ; interestingly, only 14 subjects were receiving regular AAT augmentation and they showed a trend toward better outcome [61]. Murgia et al. [62] analyzed the effect of combined AAT anomalies (PiMZ, PiSZ, and PiMS) and air pollution on COVID-19 using the AAT*air pollution global risk score. They found that the ranking of the AAT*air pollution global risk score paralleled with the ranking of countries stratified by incidence of COVID-19 deaths [62].

McElvaney et al. [63] found the IL-6:AAT ratio is markedly elevated in critically ill COVID-19 patients compared with controls and that this ratio directly correlated with prolonged hospital stay and mortality. Since this study did not specifically target AAT-deficient subjects, it suggests that relatively normal or even modestly elevated AAT levels in the face of a severe infection may be wholly inadequate. Similarly, a study of 137 hospitalized patients with COVID-19 (of whom 56 were critically ill) found that the AAT:IL-6 ratio (reverse ratio from aforementioned study) was lower in non-survivors and those with thrombosis [64]. In COVID-19-associated acute respiratory distress syndrome, manifested by increased neutrophil elastase activity, there is an excess of protease:anti-protease ratio [65]. Interestingly, IL-6 induced AAT and tocilizumab (an IL-6R antagonist) down-regulated AAT in COVID-19 [65].

In contrast with the aforementioned studies, a community-based cohort study from the U.K. showed there was no increase in either SARS-CoV-2 infection or death rates in the presence of S- or Z-AAT alleles [66]. Similarly, in 61 Swedish patients hospitalized with COVID-19, only two were found to be PiMZ and none for PiMS, PiSZ, PiSS, or PiZZ [67]. While it is difficult to reconcile these incongruent findings between AAT anomalies and hospitalized COVID-19 cases, one plausible explanation is that some with known AAT deficiency took greater precautions as evinced by the finding that the AlphaNet (AAT-deficient) population had lower case rate but greater hospitalization rate for COVID-19 during the survey period from January 2020 to February 2022 [68]. In a large genome-wide association study (GWAS) meta-analysis of over 125 000 COVID-19 cases and 2.5 million controls, SERPINA1 (AAT) gene polymorphism was not identified to be a major associative factor for severe COVID-19 [69]. However, the benefits of GWAS are well known but the limitations often overlooked. GWAS studies use power in numbers for complex and common diseases that have minor allele frequencies (MAF), typically >5% for common variants with small effects across large numbers of unrelated individuals; in contrast, genes with rare variants such as SERPINA1 with MAF <5% typically associated in related individuals with large effects would be missed. The variants in GWAS themselves are not always the causal variant but may be signal for a nearby functional variant. Additional limitations of GWAS include the epidemiological design and the methodology (SNP arrays with imputation vs. whole genome sequencing) where SNP arrays may not be designed to capture genes with rare variants [70,71]. In summary, uncommon and rare genetic variants — as illustrated by SERPINA1 genotypes that cause AAT deficiency — are not well captured by GWAS arrays [72,73]. Indeed, although one study found that the Z allele of SERPINA1 gene was associated with COPD with an odds ratio of 1.17–1.74 [74], seven other GWAS or exome-wide studies did not find an association between COPD and the Z allele [75-81]; yet, the Z-AAT allele is strongly linked clinically to COPD [82]. In other words, if AAT deficiency had not been fortuitously identified in 1963, it is unlikely that GWAS or exome-wide studies would have identified SERPINA1 variants (causing AAT deficiency) as a significant risk/associative factor for COPD.

It was reported 30 years ago, in the context of HIV infection, that an engineered AAT (α1-PDX) inhibits furin, the serine protease that cleaves the spike protein of SARS-CoV-2 before cleavage by TMPRSS2 [83,84]. Five years before the COVID-19 pandemic, AAT was reported to inhibit TMPRSS2, also required to activate the hepatitis C virus [85]. Following binding to their cell surface receptors, the coronaviruses capable of causing fatal disease — with SARS-CoV and SARS-CoV-2 binding ACE2 and MERS-CoV binding DPP4 — all require TMPRSS2 to process the viral spike protein to gain cellular entry.

Because AAT is a potent serpin, it has the potential to inhibit both TMPRSS2 and SARS-CoV-2 infection. Indeed, in HEK293T cells engineered to overexpress TMPRSS2, physiologic concentrations of AAT potently inhibited TMPRSS2 activity [86,87]. Ritzmann et al. [88] showed in both two-dimensional submerged airway epithelial cells and three-dimensional airway epithelial organoid cultures that physiologic concentrations of AAT (1 and 5 mg/ml) significantly inhibited TMPRSS2 activity and decreased intracellular burden of SARS-CoV-2 [88]. Wettstein et al. [89] also demonstrated that AAT inhibited SARS-CoV-2 infection of human airway epithelial cells (hAEc). Oguntuyo et al. [90] reported that sera from SARS-CoV-2 naïve individuals inhibited cellular entry of SARS-CoV-2 and identified AAT as the molecule responsible. AAT strongly inhibits elastase, which also cleaves the spike protein at the S1/S2 site of a SARS-CoV-2 variant [3]. Singh and co-workers [91] generated variants of SerpinB3 — through mutagenesis of its reactive center loop — that were more potent in inhibiting TMPRSS2 than AAT. Rosendal et al. [92] used a three-dimensional lung cell model using primary cells from multiple donors and found that more resistant donors to in vitro SARS-CoV-2 infection expressed higher transcript levels of SERPINA1 (AAT gene), SERPINE1, and SERPINE2 in airway cells (basal, ciliated, club, and goblet cells) [92].

Negatively charged polysaccharides are capable of augmenting the interaction between a serpin and its cognate serine protease [87,93]. Heparin has the highest negatively charge density of any biologic molecules. We found that AAT inhibition of TMPRSS2 activity and of the intracellular burden of human coronavirus 229E (HCoV-229E) in primary hAEc were augmented significantly by enoxaparin (a low molecular mass heparin) [87]. Detailed in silico modeling demonstrated: (i) suboptimal electrostatic complementarity between AAT and TMPRSS2 at both the buried interface and solvent-exposed interface rim in a molecular charge model (Figure 1A); (ii) the reactive center loop of AAT (Figure 1B, magenta) adopts an inhibitory-competent conformation compared with the crystal structure of TMPRSS2 (Figure 1B, cyan) bound to an exogenous (nafamostat) or endogenous (HAI-2) inhibitors of TMPRSS2; and (iii) negatively charged heparin (stick figures in Figure 1A–C) bridges adjacent electropositive patches at the TMPRSS2–AAT interface, neutralizing otherwise repulsive forces [87].

Figure 1.

In silico modeling demonstrating the interaction between TMPRSS2 and AAT and how heparin stabilizes the TMPRSS2–AAT complex. (A) Heparin molecules (colored stick figures) stabilize TMPRSS2–AAT association by acting as electrostatic bridges. Electrostatic potential surfaces of the TMPRSS2–AAT complex (blue = positive, red = negative) showing docked heparin 4mers binding to repelling electropositive patches at the molecular interface of TMPRSS2 and AAT. (B) Molecular surface of TMPRSS2 (cyan) showing bound reactive center loop (RCL) of AAT (magenta cartoon). Catalytic residues are labeled. P1 sidechain of AAT occupies the S1 site of TMPRSS2, superimposed on the TMPRSS2 inhibitor nafamostat (wheat). (C) Location of electropositive Lys/Arg residues (TMPRSS2 = cyan; AAT = magenta) in the vicinity of electronegative heparin (gray sticks) binding sites at the TMPRSS2(cyan)–AAT(magenta) interface. Semi-transparent molecular surface is shown, and Lys/Arg residues that contribute to unfavorable electrostatics at the interface are shown and labeled (sidechain nitrogen atoms colored blue). AAT = alpha-1-antitrypsin; TMPRSS2 = Transmembrane Protease, Serine 2. Reproduced with permission from Springer Nature (Bai et al. [87]).

Figure 1.

In silico modeling demonstrating the interaction between TMPRSS2 and AAT and how heparin stabilizes the TMPRSS2–AAT complex. (A) Heparin molecules (colored stick figures) stabilize TMPRSS2–AAT association by acting as electrostatic bridges. Electrostatic potential surfaces of the TMPRSS2–AAT complex (blue = positive, red = negative) showing docked heparin 4mers binding to repelling electropositive patches at the molecular interface of TMPRSS2 and AAT. (B) Molecular surface of TMPRSS2 (cyan) showing bound reactive center loop (RCL) of AAT (magenta cartoon). Catalytic residues are labeled. P1 sidechain of AAT occupies the S1 site of TMPRSS2, superimposed on the TMPRSS2 inhibitor nafamostat (wheat). (C) Location of electropositive Lys/Arg residues (TMPRSS2 = cyan; AAT = magenta) in the vicinity of electronegative heparin (gray sticks) binding sites at the TMPRSS2(cyan)–AAT(magenta) interface. Semi-transparent molecular surface is shown, and Lys/Arg residues that contribute to unfavorable electrostatics at the interface are shown and labeled (sidechain nitrogen atoms colored blue). AAT = alpha-1-antitrypsin; TMPRSS2 = Transmembrane Protease, Serine 2. Reproduced with permission from Springer Nature (Bai et al. [87]).

Close modal

In addition to its anticoagulant effect and its ability to augment AAT inhibition of TMPRSS2, heparin may antagonize COVID-19 by other means (Table 1). Since AAT and enoxaparin individually and synergistically antagonize several of the pathogenic mechanisms of COVID-19, we posit that they will be more effective than agents that only inhibit TMPRSS2 such as camostat [94].

Table 1.
Biological activities of alpha-1-antitrypsin and heparin that could help ameliorate severe COVID-19
Alpha-1-antitrypsin [23,87,163Heparin [164-166
Inhibits TMPRSS2 Competitively inhibits cell surface heparan sulfate, a co-receptor SARS-CoV-2 
Induces autophagy, shown to be a host-protective mechanism against MERS-CoV-2 Inhibits coagulation 
Inhibits inflammation by various mechanisms Inhibits inflammation by inhibiting NFκB activation and binding to pro-inflammatory molecules (IL-8, major basic protein, and complement components) 
Inhibits neutrophil elastase, which mediates acute lung injury and possibly processes the spike protein of SARS-CoV-2 Augments C1-esterase inhibitor (C1-INH) inhibition of kallikrein → decrease capillary leak 
Alters morphology of neutrophil extracellular traps, which is known to induce immunothrombosis of COVID-19 Reduces the release and activity of IL-6 
Inhibits thrombin Binds to extracellular histones released from dead cells, mitigating histone-mediated endothelial and organ dysfunction 
Protects endothelial cells Interacts with endothelial cells to maintain vascular integrity 
Alpha-1-antitrypsin [23,87,163Heparin [164-166
Inhibits TMPRSS2 Competitively inhibits cell surface heparan sulfate, a co-receptor SARS-CoV-2 
Induces autophagy, shown to be a host-protective mechanism against MERS-CoV-2 Inhibits coagulation 
Inhibits inflammation by various mechanisms Inhibits inflammation by inhibiting NFκB activation and binding to pro-inflammatory molecules (IL-8, major basic protein, and complement components) 
Inhibits neutrophil elastase, which mediates acute lung injury and possibly processes the spike protein of SARS-CoV-2 Augments C1-esterase inhibitor (C1-INH) inhibition of kallikrein → decrease capillary leak 
Alters morphology of neutrophil extracellular traps, which is known to induce immunothrombosis of COVID-19 Reduces the release and activity of IL-6 
Inhibits thrombin Binds to extracellular histones released from dead cells, mitigating histone-mediated endothelial and organ dysfunction 
Protects endothelial cells Interacts with endothelial cells to maintain vascular integrity 

In addition to inhibiting TMPRSS2, preventing the processing of the spike protein and cellular entry of SARS-CoV-2, AAT has a panoply of other activities that could antagonize both the intracellular virus and the multiple pathogenic mechanisms associated with severe COVID-19 (Figure 2 and Table 1) [23,95]. Such host-directed activities are less likely to be affected by SARS-CoV-2 mutations.

Mechanisms by which AAT may help antagonize SARS-CoV-2 and ameliorate the pathogenic mechanisms of COVID-19.

Figure 2.
Mechanisms by which AAT may help antagonize SARS-CoV-2 and ameliorate the pathogenic mechanisms of COVID-19.

AAT has: (i) anti-viral infection effects by inhibiting TMPRSS2 and possibly through induction of autophagy, (ii) anti-inflammatory effects, and (iii) anti-apoptotic and anti-elastase functions, protecting infected cells from injury and death. An increase in protease (neutrophil elastase, MMP-2, MMP-12) to anti-protease ratio may not only deplete AAT but elastase and MMP-12 are known to cleave AAT at a site other than the reactive center loop of AAT (denoted by inhibitory red ‘arrows’). AAT = alpha-1-antitrypsin; ACE2 = angiotensin converting enzyme 2; MMP-2 = matrix metalloproteinase-2; MMP-12 = matrix metalloproteinase-12; NETs = neutrophil extracellular traps; TMPRSS2 = Transmembrane Protease, Serine 2.

Figure 2.
Mechanisms by which AAT may help antagonize SARS-CoV-2 and ameliorate the pathogenic mechanisms of COVID-19.

AAT has: (i) anti-viral infection effects by inhibiting TMPRSS2 and possibly through induction of autophagy, (ii) anti-inflammatory effects, and (iii) anti-apoptotic and anti-elastase functions, protecting infected cells from injury and death. An increase in protease (neutrophil elastase, MMP-2, MMP-12) to anti-protease ratio may not only deplete AAT but elastase and MMP-12 are known to cleave AAT at a site other than the reactive center loop of AAT (denoted by inhibitory red ‘arrows’). AAT = alpha-1-antitrypsin; ACE2 = angiotensin converting enzyme 2; MMP-2 = matrix metalloproteinase-2; MMP-12 = matrix metalloproteinase-12; NETs = neutrophil extracellular traps; TMPRSS2 = Transmembrane Protease, Serine 2.

Close modal

AAT protects against microbes including RNA viruses

AAT augments host immunity via several mechanisms against various pathogens including influenza [96], HIV [97–101], Pseudomonas aeruginosa [102], Mycobacterium intracellulare [103], and Streptococcus pneumoniae [104]. AAT reduced the burden of cell-associated M. intracellulare through induction of autophagy [103]. Since autophagy has been implicated in controlling MERS-CoV [105], AAT-induced autophagy is a plausible mechanism by which SARS-CoV-2 is killed.

AAT has potent anti-inflammatory activities

AAT inhibits production of pro-inflammatory cytokines [63,103,106–113], induces expression of the anti-inflammatory IL-1Ra [112], and skews T cell differentiation toward the T regulatory phenotype [114]. These anti-inflammatory effects of AAT — augmented by an increase in sialylation of AAT [110] — could mitigate the injurious hyperinflammatory response typically seen seven to 10 days after the symptom onset of severe COVID-19. In contrast with the anti-inflammatory effects of glucocorticoids, AAT induces a more selective cytokine shift toward resolution; e.g. suppression of pro-inflammatory cytokines plus induction of endogenous IL-1Ra, whereas glucocorticoid causes a more global immunosuppression including inhibition of IL-1Ra expression [112]. Interestingly, when AAT and glucocorticoid are combined in macrophages, lower glucocorticoid concentrations used allowed up-regulation of IL-1Ra, whereas higher glucocorticoid levels antagonized the effects of AAT [112]. Vitamin D deficiency may also lead to decreased release of AAT from T cells, causing decreased release of the anti-inflammatory cytokine IL-10 [115,116]. Tumpara et al. [117] showed that recombinant AAT (made in Chinese hamster ovary cells) was more potent than plasma-derived AAT in inhibiting pro-inflammatory cytokine production from peripheral blood mononuclear cells stimulated with both lipopolysaccharide and spike proteins.

Recently, we reported the novel finding that AAT binds to the cytoplasmic glucocorticoid receptor (GR) in macrophages, with the AAT–GR complex having gene regulatory, anti-inflammatory, and host-defense properties [118]. Perhaps relevant to COVID-19, we found that the AAT–GR complex inhibited IL-8 production from stimulated macrophages. Since IL-8 is a potent chemokine for neutrophils and neutrophilia is a poor prognostic marker for COVID-19 [119], AAT antagonism of IL-8 production may be another mechanism against COVID-19.

Role of proteases in acute lung injury and antagonism by AAT

AAT has been shown to protect the lungs from acute lung injury [120,121]. Since an imbalance of protease and anti-protease is implicated in the pathogenesis of COVID-19 acute lung injury, absolute or relative deficiency of functional AAT is a plausible risk factor for severe COVID-19 [122,123]. In 39 critically ill patients with COVID-19, the median AAT level was modestly increased (by 1.5-fold the upper limits of normal), but there was a disproportionately increase in blood matrix metalloproteinase-12 (MMP-12, produced mainly by macrophages) and neutrophil elastase by ≥10-fold and four- to seven-fold, respectively [124]. Furthermore, the peak MMP-12 and neutrophil elastase levels were higher in those who subsequently died. When AAT phenotype was analyzed temporally, there was an increase in sialylation of the M0 and M1 AAT glycoforms in all those who died and in 59% of those who survived, suggesting that a shift in sialylation was a counterregulatory response to increase anti-elastase activity in these critically ill COVID-19 patients [124]. Interestingly, the increased protease:anti-protease ratio seen with COVID-19 may be due to cleavage of AAT by proteases, as evinced by increased AAT fragments C-36 (cleavage product of neutrophil elastase) and C-42 (cleavage product of MMP-12) (Figure 2) [125]. Additionally, cathepsin B may play a role in the hyperinflammatory response of COVID-19 [126] and AAT inhibits neutrophil elastase induction of cathepsin B in vivo and in vitro (Figure 2) [127]. Elastase also induces MMP-2, the plasma levels of which correlated with in-hospital death in patients with severe COVID-19 [128]. Through AAT inhibition of neutrophil elastase, subsequent inhibition of MMP-2 production is another mechanism by which AAT antagonizes injury to the lung extracellular matrix (Figure 2) [127,129]. AAT also has been shown to have anti-apoptotic function in epithelial and endothelial cells [130,131] (Figure 2), which may not be necessarily dependent on its anti-elastase activity as has been shown for protection against hepatocellular death [132]. In assessing lung function 12 months after recovery from COVID-19, those with PiMS and PiMZ genotypes had lower AAT levels (compared with PiMM), especially in those with persistently impaired lung function [133].

In 31 patients with SARS-CoV-2 infection, plasma levels of exosome-associated neutrophil elastase were elevated compared with control subjects and positively correlated with signs of endothelial damage and circulating AAT levels [134]. Whereas AAT was able to inhibit purified neutrophil elastase in macrovascular endothelial cells, exosome-associated neutrophil elastase was resistant to AAT inhibition.

AAT inhibition of ADAM17 antagonizes several pathogenic mechanisms of COVID-19

ADAM17 is a cell surface protease that causes shedding of ACE2, the cell surface receptor for SARS-CoV-2 [135] (Figure 3A). While this cleavage would theoretically reduce initial binding SARS-CoV-2 to the cell membrane, reduction of membrane-bound ACE2 (mACE2) may increase lung injury and edema because ACE2 has been shown to protect the lungs from injury — by reducing both bradykinin production and neutrophil infiltration as well as catalyzing angiotensin II to the anti-inflammatory angiotensin-(1–7) and angiotensin-(1–9); both metabolic products of angiotensin II also protect lung epithelial cells from death [136–138]. ADAM17, aka TNF converting enzyme, also cleaves membrane-bound TNF to its soluble form, perpetuating the inflammatory response including the induction of MMP-2 (Figure 3A).

Mechanisms by which ADAM17 may contribute to the hyperinflammatory pathogenesis of COVID-19.

Figure 3.
Mechanisms by which ADAM17 may contribute to the hyperinflammatory pathogenesis of COVID-19.

(A) ADAM17, also known as TNF converting enzyme, is able to cleave membrane-bound TNF (mTNF) to soluble TNF (sTNF), enhancing the inflammatory and injurious response such as acute lung injury and edema. In addition, the inflammatory response induces MMP-2 in neutrophils, causing further injury to the lung extracellular matrix. Activated ADAM17 is also cleaves mACE2 to soluble ACE2 (sACE2). This process may enhance inflammation by preventing mACE2 from catalyzing pro-inflammatory angiotensin to the less inflammatory metabolites (angiotensin–(1–7) and angiotensin–(1–9)). While soluble ACE2 is able to bind free virus, reduction in mACE2 increases both inflammation and egress of newly synthesized viral particles to infect other cells. (B) During the basal state, IL-6 signals by first binding to membrane-bound IL-6R (on macrophages), followed by engagement of the IL-6-IL-6R complex with gp130, which contains an intracellular signaling moiety that IL-6R lacks. The classical type of IL-6 signaling is known as cis-IL-6 signaling. (C) During an inflammatory state (insult), the cell surface protein ADAM17 is activated and cleaves membrane-bound IL-6R (mIL-6R) from the cell surface. The soluble IL-6R (sIL-6R) binds to IL-6 and the complex can directly bind to gp130 on all cell types to provide another mode of signaling that is more widespread and known as trans-IL-6 signaling. ACE2 = angiotensin converting enzyme 2; ADAM17 = a disintegrin and metalloprotease 17; IL-6 = interleukin-6; IL-6R = IL-6 receptor; MMP2 = matrix metalloproteinase-2; TNF = tumor necrosis factor.

Figure 3.
Mechanisms by which ADAM17 may contribute to the hyperinflammatory pathogenesis of COVID-19.

(A) ADAM17, also known as TNF converting enzyme, is able to cleave membrane-bound TNF (mTNF) to soluble TNF (sTNF), enhancing the inflammatory and injurious response such as acute lung injury and edema. In addition, the inflammatory response induces MMP-2 in neutrophils, causing further injury to the lung extracellular matrix. Activated ADAM17 is also cleaves mACE2 to soluble ACE2 (sACE2). This process may enhance inflammation by preventing mACE2 from catalyzing pro-inflammatory angiotensin to the less inflammatory metabolites (angiotensin–(1–7) and angiotensin–(1–9)). While soluble ACE2 is able to bind free virus, reduction in mACE2 increases both inflammation and egress of newly synthesized viral particles to infect other cells. (B) During the basal state, IL-6 signals by first binding to membrane-bound IL-6R (on macrophages), followed by engagement of the IL-6-IL-6R complex with gp130, which contains an intracellular signaling moiety that IL-6R lacks. The classical type of IL-6 signaling is known as cis-IL-6 signaling. (C) During an inflammatory state (insult), the cell surface protein ADAM17 is activated and cleaves membrane-bound IL-6R (mIL-6R) from the cell surface. The soluble IL-6R (sIL-6R) binds to IL-6 and the complex can directly bind to gp130 on all cell types to provide another mode of signaling that is more widespread and known as trans-IL-6 signaling. ACE2 = angiotensin converting enzyme 2; ADAM17 = a disintegrin and metalloprotease 17; IL-6 = interleukin-6; IL-6R = IL-6 receptor; MMP2 = matrix metalloproteinase-2; TNF = tumor necrosis factor.

Close modal

Both membrane-bound and soluble IL-6R have pro-inflammatory function but the former occurs mostly in macrophages, whereas the latter occurs in all cell types (Figure 3B,C). Upon binding of IL-6 to membrane-bound IL-6R, the IL-6–IL-6R complex engages gp130, a cell surface molecule that transmits downstream intracellular signaling, a process known as cis-IL-6 signaling (Figure 3B,C, left-hand side). Soluble IL-6R binding to IL-6 can also bind to gp130, a process known as trans-IL-6 signaling (Figure 3C, right-hand side). During inflammatory states, ADAM17 is activated and cleaves membrane forms of IL-6 and IL-6R to their soluble forms [139–141], resulting in more widespread IL-6-mediated inflammation (Figure 3C). ADAM17 also induces shedding of fractalkine, a membrane-bound chemokine that facilitates intercellular adhesion and mainly found in neurons and endothelial cells [142]; thus, ADAM17 may reduce intercellular adhesion between endothelial cells.

AAT inhibits activity of ADAM17 [106,132,143]. Given that ADAM17 may augment inflammation and other mechanisms that promote lung injury, AAT inhibition of ADAM17 is likely to be anti-inflammatory and to protect the lungs from injury. While AAT inhibition of ADAM17 could also preserve ACE2 on the cell surface, such preservation of the receptor for SARS-CoV-2 may paradoxically decrease viral infectivity to other cells by decreasing the egress of newly synthesized viral particles [138,144].

The role of neutrophil extracellular traps in the immunothrombosis of severe COVID-19 and possible antagonism by AAT

Elevated absolute neutrophil number, increased neutrophil percentage, and high neutrophil:lymphocyte ratio in the blood predict progression to severe COVID-19 [119]. One study showed that neutrophil:lymphocyte ratio ≥4.5 and ≥6.5 were associated with significantly increased severity and mortality, respectively [145]. There is also increasing evidence that aberrant formation of neutrophil extracellular traps (NETs) — comprised of neutrophil-derived decondensed chromatin decorated with elastase, cathepsin G, and histones — play a pathogenic role in the immunothrombosis, mucous secretions, and cytokine production seen with severe COVID-19 [146-152]. In hospitalized patients with COVID-19, increased NETs formation was found in the plasma, tracheal secretions, and lung tissues [152]. In post-mortem lung tissues of individuals who died from COVID-19, NETs were found in the airways, interstitium, and arterioles [151]. Since elastase plays a key role in NETs formation by degrading specific histones and promoting chromatin decondensation [153], AAT has the potential to inhibit pathogenic NETs formation [154]. This notion is supported by an ex vivo pre-COVID-19 study showing that AAT is able to change the shape and adherence of NETs [155]. However, in the bronchoalveolar lavage fluid of COVID-19 patients, it was found that AAT–elastase complex was not found (due to elastase binding to acute phase proteins, histones, and C3) and that exogenous AAT did bind to NETs but did not qualitatively inhibit NETs formation [156].

AAT is presently administered to patients with confirmed AAT deficiency and airflow limitation [82]. A patient survey of AAT-deficient patients showed that AAT replacement reduced the number and severity of lung infections [157]. In 19 AAT-deficient emphysema patients in whom AAT was abruptly discontinued due to insurance reimbursement issues, the number of pulmonary exacerbations — historically often due to viral or bacterial infections — dramatically rose [158].

A 43-year-old woman with cystic fibrosis, who developed severe respiratory deterioration with marked increase in pro-inflammatory cytokines in the airways and the blood following acquisition of COVID-19, was administered intravenous AAT at 120 mg/kg/week for four consecutive weeks [159]. Following each AAT dose, both plasma and airway IL-1β, IL-6, and IL-8 levels decreased and airway neutrophil elastase level decreased, accompanied by clinical and radiographic improvements [159].

An open-label study administered AAT to nine patients requiring hospitalization for mild or moderate COVID-19 — four received inhaled AAT at 100 mg/day for 7 days while five received inhaled AAT at the same dose plus intravenous AAT at 60 mg/kg on Days 1, 3, and 5 [88]. Two of the patients also received remdesivir and two received dexamethasone. In all nine patients, the oxygenation improved, serum C-reactive protein decreased, and all were discharged in good functional status. While there was no control group in this study, an analysis of a contemporaneous observational cohort (CORSAAR) of 23 COVID-19 patients matched for age and disease severity revealed three COVID-19 deaths and a delayed decrease in C-reactive protein in the historical ‘control’ group that did not receive exogenous AAT [88]. Three Israeli patients who were critically ill with COVID-19 (all mechanically ventilated) were administered three doses of intravenous AAT (1–2 days apart) early in the hospitalization (initiated Day 2–7 of hospitalization) and all improved objectively (as measured by the SOFA score and PaO2/FiO2 ratio) within a day of administering the AAT; a fourth patient who received only one dose of AAT at ∼Day 21 of hospitalization succumbed [160]. In a phase 2, multi-center, randomized, double-blind, placebo-controlled trial of 36 patients with moderate to severe COVID-19-associated acute respiratory distress syndrome who received either weekly placebo (n = 11), weekly intravenous AAT at 120 mg per kg (n = 13), or AAT once followed by weekly placebo (n = 12), AAT treatment (in the two latter groups) resulted in significant decrease in IL-6 compared with the placebo group at 1 week [161]. However, AAT administration (n = 25) also reduced soluble receptor for TNF [161], which may increase free TNF. While there was no difference in mortality or ventilator-free days, the AAT-treated patients had a trend toward decreased time on the ventilator P = 0.44 [161]. Strassmair and Stangl [162] have proposed the idea that delivery of mesenchymal stem cells that express AAT, with their ability to ‘home-in’ to the lungs, might be an effective mechanism to deliver AAT.

Several large studies demonstrate robust epidemiologic association between AAT deficiency and increased COVID-19 infection, hospitalization, severe disease, and mortality. Enoxaparin augments AAT inhibition of TMPRSS2 activity and thus may synergize with AAT in inhibiting SARS-CoV-2 entry of cells. Because both AAT and enoxaparin have biological properties that antagonize several pathogenic mechanisms of COVID-19, this pharmaceutical combination is promising for those critically ill from recalcitrant COVID-19. Thus, future translational investigations and clinical trials should be undertaken with combined AAT and enoxaparin in patients who are severely ill with COVID-19.

  • While there are effective vaccines against the prevention of severe COVID-19, treatment for patients who are critically ill with COVID-19 remains suboptimal.

  • Based on the emerging evidence that AAT inhibits SARS-CoV-2 infection and many of the pathogenic mechanisms of COVID-19, a review of this topic is timely.

  • Several large studies demonstrate robust epidemiologic association between AAT deficiency and increased COVID-19 infection, hospitalization, severe disease, and mortality. Enoxaparin, a low molecular mass heparin, augments AAT inhibition of TMPRSS2 activity and thus may synergize with AAT in inhibiting SARS-CoV-2 entry of cells. Because both AAT and enoxaparin have biological properties that antagonize several pathogenic mechanisms of COVID-19, this pharmaceutical combination is promising for those critically ill from recalcitrant COVID-19. Thus, future translational investigations and clinical trials should be undertaken with combined AAT and enoxaparin in patients who are severely ill with COVID-19.

The authors declare that there are no competing interests associated with the manuscript.

This work is funded by Veterans Affairs Merit Award, 1 I01 BX005651-01A2. We are also grateful to Nina C. Khoo, M.D. for her generous and kind support.

AAT

alpha-1-antitrypsin

ACE2

angiotensin converting enzyme 2

COPD

chronic obstructive pulmonary disease

GR

glucocorticoid receptor

GWAS

genome-wide association study

hAEc

human airway epithelial cells

IL-1

interleukin-1

IL-6R

IL-6 receptor

MAF

minor allele frequencies

MMP-12

metalloproteinase-12

PiMM

protease inhibitor MM

TMPRSS2

transmembrane protease 2

TNF

tumor necrosis factor

1
Hoffmann
,
M.
,
Kleine-Weber
,
H.
,
Schroeder
,
S.
,
Krüger
,
N.
,
Herrler
,
T.
,
Erichsen
,
S.
et al (
2020
)
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
.
Cell
181
,
271
280
2
Coutard
,
B.
,
Valle
,
C.
,
de Lamballerie
,
X.
,
Canard
,
B.
,
Seidah
,
N.G.
and
Decroly
,
E.
(
2020
)
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
.
Antiviral Res.
176
,
104742
3
Bhattacharyya
,
C.
,
Das
,
C.
,
Ghosh
,
A.
,
Singh
,
A.K.
,
Mukherjee
,
S.
,
Majumder
,
P.P.
et al (
2021
)
SARS-CoV-2 mutation 614G creates an elastase cleavage site enhancing its spread in high AAT-deficient regions
.
Infect. Genet. Evol.
90
,
104760
4
(
2022
)
Centers for
Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
5
(
2022
)
Centers for Disease Control and Prevention. Science brief: Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
6
(
2022
)
Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
7
Greaney
,
A.J.
,
Starr
,
T.N.
,
Gilchuk
,
P.
,
Zost
,
S.J.
,
Binshtein
,
E.
,
Loes
,
A.N.
et al (
2021
)
Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
.
Cell Host Microbe
29
,
44
57
8
Ioannou
,
G.N.
,
Locke
,
E.
,
Green
,
P.
,
Berry
,
K.
,
O'Hare
,
A.M.
,
Shah
,
J.A.
et al (
2020
)
Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection
.
JAMA Netw. Open
3
,
e2022310
9
Sabino
,
E.C.
,
Buss
,
L.F.
,
Carvalho
,
M.P.S.
,
Prete
, Jr.,
C.A.
,
Crispim
,
M.A.E.
,
Fraiji
,
N.A.
et al (
2021
)
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
.
Lancet
397
,
452
455
10
Charness
,
M.E.
,
Gupta
,
K.
,
Stack
,
G.
,
Strymish
,
J.
,
Adams
,
E.
,
Lindy
,
D.C.
et al (
2022
)
Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment
.
N. Engl. J. Med.
387
,
1045
1047
11
Wen
,
W.
,
Chen
,
C.
,
Tang
,
J.
,
Wang
,
C.
,
Zhou
,
M.
,
Cheng
,
Y.
et al (
2022
)
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis
.
Ann. Med.
54
,
516
523
12
CDC. COVID data tracker: Variant proportions. Accessed Jan. 6, 2023
13
Ai
,
J.
,
Zhang
,
H.
,
Zhang
,
Y.
,
Lin
,
K.
,
Zhang
,
Y.
,
Wu
,
J.
et al (
2022
)
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
.
Emerg. Microbes Infect.
11
,
337
343
14
Collie
,
S.
,
Nayager
,
J.
,
Bamford
,
L.
,
Bekker
,
L.G.
,
Zylstra
,
M.
and
Gray
,
G.
(
2022
)
Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa
.
N. Engl. J. Med.
387
,
1332
1333
15
Hentzien
,
M.
,
Autran
,
B.
,
Piroth
,
L.
,
Yazdanpanah
,
Y.
and
Calmy
,
A.
(
2022
)
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
.
Lancet Infect. Dis.
22
,
1278
16
Le
,
T.T.B.
,
Vasanthakumaran
,
T.
,
Thi Hien
,
H.N.
,
Hung
,
I.C.
,
Luu
,
M.N.
,
Khan
,
Z.A.
et al (
2022
)
SARS-CoV-2 Omicron and its current known unknowns: a narrative review
.
Rev. Med. Virol.
23
,
e2398
17
Qu
,
P.
,
Evans
,
J.P.
,
Faraone
,
J.N.
,
Zheng
,
Y.M.
,
Carlin
,
C.
,
Anghelina
,
M.
et al (
2022
)
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
.
Cell Host Microbe
31
,
9
17
18
Razonable
,
R.R.
,
Tulledge-Scheitel
,
S.M.
,
Hanson
,
S.N.
,
Arndt
,
R.F.
,
Speicher
,
L.L.
,
Seville
,
T.A.
et al (
2022
)
Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of high-risk persons with coronavirus disease 2019 during the omicron epoch
.
Open Forum Infect. Dis.
9
,
ofac411
19
Tamura
,
T.
,
Ito
,
J.
,
Uriu
,
K.
,
Zahradnik
,
J.
,
Kida
,
I.
,
Nasser
,
H.
et al (
2023
)
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. bioRxiv
20
Wang
,
Q.
,
Guo
,
Y.
,
Iketani
,
S.
,
Nair
,
M.S.
,
Li
,
Z.
,
Mohri
,
H.
et al (
2022
)
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
.
Nature
608
,
603
608
21
Yue
,
C.
,
Song
,
W.
,
Wang
,
L.
,
Jian
,
F.
,
Chen
,
X.
,
Gao
,
F.
et al (
2023
)
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
.
Lancet Infect. Dis.
23
,
278
280
22
Arnaldez
,
F.I.
,
O'Day
,
S.J.
,
Drake
,
C.G.
,
Fox
,
B.A.
,
Fu
,
B.
,
Urba
,
W.J.
et al (
2020
)
The society for immunotherapy of cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
.
J. Immunother. Cancer
8
,
e000930
23
Bai
,
X.
,
Hippensteel
,
J.
,
Leavitt
,
A.
,
Maloney
,
J.P.
,
Beckham
,
D.
,
Garcia
,
C.
et al (
2021
)
Hypothesis: alpha-1-antitrypsin is a promising treatment option for COVID-19
.
Med. Hypotheses
146
,
110394
24
Del Valle
,
D.M.
,
Kim-Schulze
,
S.
,
Huang
,
H.H.
,
Beckmann
,
N.D.
,
Nirenberg
,
S.
,
Wang
,
B.
et al (
2020
)
An inflammatory cytokine signature predicts COVID-19 severity and survival
.
Nat. Med.
26
,
1636
1643
25
El-Solh
,
A.A.
,
Meduri
,
U.G.
,
Lawson
,
Y.
,
Carter
,
M.
and
Mergenhagen
,
K.A.
(
2021
)
Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository
.
J. Intensive Care Med.
36
,
664
672
26
Zhou
,
F.
,
Yu
,
T.
,
Du
,
R.
,
Fan
,
G.
,
Liu
,
Y.
,
Liu
,
Z.
et al (
2020
)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
.
Lancet
395
,
1054
1062
27
Pedersen
,
S.F.
and
Ho
,
Y.-C.
(
2020
)
SARS-CoV-2: a storm is raging
.
J. Clin. Invest.
130
,
2202
2205
28
Horby
,
P.
,
Lim
,
W.S.
,
Emberson
,
J.R.
,
Mafham
,
M.
,
Bell
,
J.L.
,
Linsell
,
L.
et al (
2020
)
Dexamethasone in hospitalized patients with COVID-19
.
N. Engl. J. Med.
384
,
693
704
29
Beigel
,
J.H.
,
Tomashek
,
K.M.
,
Dodd
,
L.E.
,
Mehta
,
A.K.
,
Zingman
,
B.S.
,
Kalil
,
A.C.
et al (
2020
)
Remdesivir for the treatment of COVID-19 - final report
.
N. Engl. J. Med.
383
,
1813
1826
30
WHO Solidarity Trial Consortium
. (
2021
)
Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results
.
N. Engl. J. Med.
384
,
497
511
31
Bose
,
D.
,
Gogtay
,
N.J.
and
Rajan
,
S.K.
(
2021
)
Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective
.
Lung India
38
,
382
386
32
CORIMUNO-19 Collaborative Group
. (
2021
)
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
.
Lancet Respir. Med.
9
,
295
304
33
Audemard-Verger
,
A.
,
Le Gouge
,
A.
,
Pestre
,
V.
,
Courjon
,
J.
,
Langlois
,
V.
,
Vareil
,
M.O.
et al (
2022
)
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: a randomized controlled trial
.
PLoS One
17
,
e0269065
34
Davidson
,
M.
,
Menon
,
S.
,
Chaimani
,
A.
,
Evrenoglou
,
T.
,
Ghosn
,
L.
,
Graña
,
C.
et al (
2022
)
Interleukin-1 blocking agents for treating COVID-19
.
Cochrane Database Syst. Rev.
1
,
CD015308
35
Kyriazopoulou
,
E.
,
Huet
,
T.
,
Cavalli
,
G.
,
Gori
,
A.
,
Kyprianou
,
M.
,
Pickkers
,
P.
et al (
2021
)
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
.
Lancet Rheumatol.
3
,
e690
e697
36
Yang
,
C.
,
Keshavjee
,
S.
and
Liu
,
M.
(
2020
)
Alpha-1 antitrypsin for COVID-19 treatment: Dual role in antiviral infection and anti-inflammation
.
Front. Pharmacol.
11
,
615398
37
RECOVERY Collaborative Group
. (
2021
)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
Lancet
397
,
1637
1645
38
Martini
,
F.
,
De Mattei
,
M.
,
Contini
,
C.
and
Tognon
,
M.G.
(
2020
)
Potential use of alpha-1 anti-trypsin in the COVID-19 treatment
.
Front. Cell Dev. Biol.
8
,
577528
39
de Serres
,
F.J.
,
Blanco
,
I.
and
Fernández-Bustillo
,
E.
(
2003
)
Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America
.
Clin. Genet.
64
,
382
397
40
Hazari
,
Y.M.
,
Bashir
,
A.
,
Habib
,
M.
,
Bashir
,
S.
,
Habib
,
H.
,
Qasim
,
M.A.
et al (
2017
)
Alpha-1-antitrypsin deficiency: genetic variations, clinical manifestations and therapeutic interventions
.
Mutat. Res.
773
,
14
25
41
Stoller
,
J.
and
Brantly
,
M.
(
2013
)
The challenge of detecting alpha-1 antitrypsin deficiency
.
COPD
10
,
26
34
42
Lieberman
,
J.
,
Winter
,
B.
and
Sastre
,
A.
(
1986
)
Alpha1-antitrypsin Pi-types in 965 COPD patients
.
Chest
89
,
370
373
43
Greulich
,
T.
and
Vogelmeier
,
C.F.
(
2016
)
Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis
.
Ther. Adv. Respir. Dis.
10
,
72
84
44
Shimi
,
G.
,
Sohrab
,
G.
,
Pourvali
,
K.
,
Ghorbani
,
A.
,
Balam
,
F.H.
,
Rostami
,
K.
et al (
2021
)
Correlation of low levels of alpha-1 antitrypsin and elevation of neutrophil to lymphocyte ratio with higher mortality in severe COVID-19 patients
.
Mediat. Inflamm.
2021
,
5555619
45
Abd
,
H.A.
,
Kasim
,
A.A.
and
Shareef
,
L.G.
(
2022
)
Serum levels of a1-antitrypsin, interleukin-1b and interleukin-6 in Iraqi COVID-19 patients: a cross-sectional study
.
F1000Res
11
,
921
46
Taggart
,
C.
,
Cervantes-Laurean
,
D.
,
Kim
,
G.
,
McElvaney
,
N.G.
,
Wehr
,
N.
,
Moss
,
J.
et al (
2000
)
Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity
.
J. Biol. Chem.
275
,
27258
27265
47
Strnad
,
P.
,
McElvaney
,
N.G.
and
Lomas
,
D.A.
(
2020
)
Alpha1-antitrypsin deficiency
.
N. Engl. J. Med.
382
,
1443
1455
48
Alam
,
S.
,
Li
,
Z.
,
Janciauskiene
,
S.
and
Mahadeva
,
R.
(
2011
)
Oxidation of Z α1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema
.
Am. J. Respir. Cell Mol. Biol.
45
,
261
269
49
Wang
,
J.Z.
,
Zhang
,
R.Y.
and
Bai
,
J.
(
2020
)
An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients
.
Int. J. Cardiol.
312
,
137
138
50
Guttman
,
O.
,
Baranovski
,
B.M.
,
Schuster
,
R.
,
Kaner
,
Z.
,
Freixo-Lima
,
G.S.
,
Bahar
,
N.
et al (
2015
)
Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats
.
Clin. Exp. Immunol.
179
,
161
172
51
Vianello
,
A.
and
Braccioni
,
F.
(
2020
)
Geographical overlap between alpha-1 antitrypsin deficiency and COVID-19 infection in Italy: casual or causal?
Arch. Bronconeumol.
56
,
609
610
52
Ferrarotti
,
I.
,
Ottaviani
,
S.
,
Balderacchi
,
A.M.
,
Barzon
,
V.
,
De Silvestri
,
A.
,
Piloni
,
D.
et al (
2021
)
COVID-19 infection in severe alpha 1-antitrypsin deficiency: looking for a rationale
.
Respir. Med.
183
,
106440
53
Shapira
,
G.
,
Shomron
,
N.
and
Gurwitz
,
D.
(
2020
)
Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates
.
FASEB J.
34
,
14160
14165
54
Yoshikura
,
H.
(
2021
)
Epidemiological correlation between COVID-19 epidemic and prevalence of alpha-1 antitrypsin deficiency in the world
.
Global Health Med.
3
,
73
81
55
Blanco
,
I.
,
de Serres
,
F.J.
,
Fernandez-Bustillo
,
E.
,
Lara
,
B.
and
Miravitlles
,
M.
(
2006
)
Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries
.
Eur. Respir. J.
27
,
77
84
56
Dutta
,
A.K.
and
Goswami
,
K.
(
2021
)
Host genomics of COVID-19: evidence point towards alpha 1 antitrypsin deficiency as a putative risk factor for higher mortality rate
.
Med. Hypotheses
147
,
110485
57
Faria
,
N.
,
Inês Costa
,
M.
,
Gomes
,
J.
and
Sucena
,
M.
(
2021
)
Alpha-1 antitrypsin deficiency severity and the risk of COVID-19: a Portuguese cohort
.
Respir. Med.
181
,
106387
58
Yang
,
C.
,
Chapman
,
K.R.
,
Wong
,
A.
and
Liu
,
M.
(
2021
)
α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action
.
Lancet Respir. Med.
9
,
337
339
59
Pertzov
,
B.
,
Shapira
,
G.
,
Abushkara
,
S.
,
Cohen
,
S.
,
Turjeman
,
A.
,
Kramer
,
M.R.
et al (
2022
)
Lower serum alpha 1 antitrypsin levels in patients with severe COVID-19 compared with patients hospitalized due to non-COVID-19 pneumonia
.
Infect. Dis. (Lond.)
54
,
846
851
60
Hermosa
,
R.
,
Vargas Centanaro
,
J.L.
,
González Castro
,
G.
,
Miravitlles
,
M.E.
,
Lázaro-Asegurado
,
M.
,
Jiménez-Rodríguez
,
L.
et al (
2023
)
Severe COVID-19 illness and α1-antitrypsin deficiency: COVID-AATD study
.
Biomedicines
11
,
516
61
Parr
,
D.G.
,
Chorostowska-Wynimko
,
J.
,
Corsico
,
A.
,
Esquinas
,
C.
,
McElvaney
,
G.N.
,
Sark
,
A.D.
et al (
2022
)
Impact of COVID-19 in patients With severe alpha-1 antitrypsin deficiency: the IMCA1 study of the EARCO clinical research collaboration
.
Arch. Bronconeumol.
58
,
840
842
62
Murgia
,
N.
,
Corsico
,
A.G.
,
D'Amato
,
G.
,
Maesano
,
C.N.
,
Tozzi
,
A.
and
Annesi-Maesano
,
I.
(
2021
)
Do gene-environment interactions play a role in COVID-19 distribution? The case of alpha-1 antitrypsin, air pollution and COVID-19
.
Multidiscip. Respir. Med.
16
,
741
63
McElvaney
,
O.J.
,
McEvoy
,
N.L.
,
McElvaney
,
O.F.
,
Carroll
,
T.P.
,
Murphy
,
M.P.
,
Dunlea
,
D.M.
et al (
2020
)
Characterization of the inflammatory response to severe COVID-19 illness
.
Am. J. Respir. Crit. Care Med.
202
,
812
821
64
Philippe
,
A.
,
Puel
,
M.
,
Narjoz
,
C.
,
Gendron
,
N.
,
Durey-Dragon
,
M.A.
,
Vedie
,
B.
et al (
2022
)
Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19
.
Biochimie
202
,
206
211
65
McElvaney
,
O.F.
,
Asakura
,
T.
,
Meinig
,
S.L.
,
Torres-Castillo
,
J.L.
,
Hagan
,
R.S.
,
Gabillard-Lefort
,
C.
et al (
2022
)
Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: therapeutic implications
.
EBioMedicine
77
,
103894
66
Schneider
,
C.V.
and
Strnad
,
P.
(
2021
)
SARS-CoV-2 infection in alpha1-antitrypsin deficiency
.
Respir. Med.
184
,
106466
67
Nygren
,
D.
,
Mölstad
,
U.
,
Thulesius
,
H.
,
Hillman
,
M.
,
Broman
,
L.M.
,
Tanash
,
H.
et al (
2022
)
Low prevalence of mild alpha-1-antitrypsin deficiency in hospitalized COVID-19-patients
.
Int. J. Gen. Med.
15
,
5843
5848
68
Hay
,
M.A.
,
Holm
,
K.
,
McCathem
,
J.
,
Sandhaus
,
R.A.
and
Strange
,
C.
(
2022
)
COVID-19 impact on health of alpha-1 antitrypsin deficient patients in a disease management program
.
Am. J. Respir. Crit. Care Med.
205
,
A4121
69
COVID-19 Host Genetics Initiative
. (
2022
)
A first update on mapping the human genetic architecture of COVID-19
.
Nature
608
,
E1
E10
70
Höglund
,
J.
,
Rafati
,
N.
,
Rask-Andersen
,
M.
,
Enroth
,
S.
,
Karlsson
,
T.
,
Ek
,
W.E
et al et al (
2019
)
Improved power and precision with whole genome sequencing data in genome-wide association studies of inflammatory biomarkers
.
Sci. Rep.
9
,
16844
71
Tam
,
V.
,
Patel
,
N.
,
Turcotte
,
M.
,
Bossé
,
Y.
,
Paré
,
G.
and
Meyre
,
D.
(
2019
)
Benefits and limitations of genome-wide association studies
.
Nat. Rev. Genet.
20
,
467
484
72
Manolio
,
T.A.
,
Collins
,
F.S.
,
Cox
,
N.J.
,
Goldstein
,
D.B.
,
Hindorff
,
L.A.
,
Hunter
,
D.J.
et al (
2009
)
Finding the missing heritability of complex diseases
.
Nature
461
,
747
753
73
Silverman
,
E.K.
and
Sandhaus
,
R.A.
(
2009
)
Clinical practice. Alpha1-antitrypsin deficiency
.
N. Engl. J. Med.
360
,
2749
2957
74
Moll
,
M.
,
Jackson
,
V.E.
,
Yu
,
B.
,
Grove
,
M.L.
,
London
,
S.J.
,
Gharib
,
S.A.
et al (
2021
)
A systematic analysis of protein-altering exonic variants in chronic obstructive pulmonary disease
.
Am. J. Physiol. Lung Cell Mol. Physiol.
321
,
L130
L143
75
Shrine
,
N.
,
Guyatt
,
A.L.
,
Erzurumluoglu
,
A.M.
,
Jackson
,
V.E.
,
Hobbs
,
B.D.
,
Melbourne
,
C.A.
et al (
2019
)
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries
.
Nat. Genet.
51
,
481
493
76
Sakornsakolpat
,
P.
,
Prokopenko
,
D.
,
Lamontagne
,
M.
,
Reeve
,
N.F.
,
Guyatt
,
A.L.
,
Jackson
,
V.E.
et al (
2019
)
Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations
.
Nat. Genet.
51
,
494
505
77
Wain
,
L.V.
,
Shrine
,
N.
,
Miller
,
S.
,
Jackson
,
V.E.
,
Ntalla
,
I.
,
Soler Artigas
,
M.
et al (
2015
)
Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank
.
Lancet Respir. Med.
3
,
769
781
78
Wain
,
L.V.
,
Shrine
,
N.
,
Artigas
,
M.S.
,
Erzurumluoglu
,
A.M.
,
Noyvert
,
B.
,
Bossini-Castillo
,
L.
et al (
2017
)
Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets
.
Nat. Genet.
49
,
416
425
79
Hobbs
,
B.D.
,
Parker
,
M.M.
,
Chen
,
H.
,
Lao
,
T.
,
Hardin
,
M.
,
Qiao
,
D.
et al (
2016
)
Exome array analysis identifies a common variant in IL27 associated with chronic obstructive pulmonary disease
.
Am. J. Respir. Crit. Care Med.
194
,
48
57
80
Jackson
,
V.E.
,
Latourelle
,
J.C.
,
Wain
,
L.V.
,
Smith
,
A.V.
,
Grove
,
M.L.
,
Bartz
,
T.M.
et al (
2018
)
Meta-analysis of exome array data identifies six novel genetic loci for lung function
.
Wellcome Open Res.
3
,
4
81
Jackson
,
V.E.
,
Ntalla
,
I.
,
Sayers
,
I.
,
Morris
,
R.
,
Whincup
,
P.
,
Casas
,
J.P.
et al (
2016
)
Exome-wide analysis of rare coding variation identifies novel associations with COPD and airflow limitation in MOCS3, IFIT3 and SERPINA12
.
Thorax
71
,
501
509
82
Brantly
,
M.L.
,
Lascano
,
J.E.
and
Shahmohammadi
,
A.
(
2018
)
Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence
.
Chronic Obstr. Pulm. Dis.
6
,
100
114
83
Anderson
,
E.D.
,
Thomas
,
L.
,
Hayflick
,
J.S.
and
Thomas
,
G.
(
1993
)
Inhibition of HIV-1 gp160-dependent membrane fusion by a furin directed alpha 1-antitrypsin variant
.
J. Biol. Chem.
268
,
24887
24891
84
Scott
,
B.M.
and
Sheffield
,
W.P.
(
2020
)
Engineering the serpin α1-antitrypsin: a diversity of goals and techniques
.
Protein Sci.
29
,
856
871
85
Esumi
,
M.
,
Ishibashi
,
M.
,
Yamaguchi
,
H.
,
Nakajima
,
S.
,
Tai
,
Y.
,
Kikuta
,
S.
et al (
2015
)
Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection
.
Hepatology
61
,
437
446
86
Azouz
,
N.P.
,
Klingler
,
A.M.
,
Callahan
,
V.
,
Akhrymuk
,
I.V.
,
Elez
,
K.
,
Raich
,
L.
et al (
2021
)
Alpha 1 antitrypsin is an inhibitor of the SARS-CoV2-priming protease TMPRSS2
.
Pathog. Immun.
6
,
55
74
87
Bai
,
X.
,
Buckle
,
A.M.
,
Vladar
,
E.K.
,
Janoff
,
E.N.
,
Khare
,
R.
,
Ordway
,
D.
et al (
2022
)
Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19
.
Sci. Rep.
12
,
5207
88
Ritzmann
,
F.
,
Chitirala
,
P.
,
Krüger
,
N.
,
Hoffmann
,
M.
,
Zuo
,
W.
,
Lammert
,
F.
et al (
2021
)
Therapeutic application of alpha-1-antitrypsin in COVID-19
.
Am. J. Respir. Crit. Care Med.
204
,
224
227
89
Wettstein
,
L.
,
Weil
,
T.
,
Conzelmann
,
C.
,
Müller
,
J.A.
,
Groß
,
R.
,
Hirschenberger
,
M.
et al (
2021
)
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection
.
Nat. Commun.
12
,
1726
90
Oguntuyo
,
K.Y.
,
Stevens
,
C.S.
,
Siddiquey
,
M.N.
,
Schilke
,
R.M.
,
Woolard
,
M.D.
,
Zhang
,
H.
et al (
2020
)
In plain sight: the role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics. bioRxiv
91
Singh
,
S.
,
O'Reilly
,
S.
,
Gewaid
,
H.
,
Bowie
,
A.G.
,
Gautier
,
V.
and
Worrall
,
D.M.
(
2022
)
Reactive centre loop mutagenesis of SerpinB3 to target TMPRSS2 and furin: inhibition of SARS-CoV-2 cell entry and replication
.
Int. J. Mol. Sci.
23
,
12522
92
Rosendal
,
E.
,
Mihai
,
I.S.
,
Becker
,
M.
,
Das
,
D.
,
Frängsmyr
,
L.
,
Persson
,
B.D.
et al (
2022
)
Serine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections
.
mBio
13
,
e0089222
93
Dijk
,
M.
,
Holkers
,
J.
,
Voskamp
,
P.
,
Giannetti
,
B.M.
,
Waterreus
,
W.J.
,
van Veen
,
H.A.
et al (
2016
)
How dextran sulfate affects C1-inhibitor activity: a model for polysaccharide potentiation
.
Structure
24
,
2182
2189
94
Gunst
,
J.D.
,
Staerke
,
N.B.
,
Pahus
,
M.H.
,
Kristensen
,
L.H.
,
Bodilsen
,
J.
,
Lohse
,
N.
et al (
2021
)
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19-a double-blind randomized controlled trial
.
EClinicalMedicine
35
,
100849
95
Marzouk
,
S.
,
Attia
,
N.
and
Mashal
,
M.
(
2021
)
Insights into the potential role of alpha1-antitrypsin in COVID-19 patients: mechanisms, current update, and future perspectives
.
Clin. Respir. J.
15
,
1019
1024
96
Harbig
,
A.
,
Mernberger
,
M.
,
Bittel
,
L.
,
Pleschka
,
S.
,
Schughart
,
K.
,
Steinmetzer
,
T.
et al (
2020
)
Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airway
.
J. Biol. Chem.
295
,
11388
11407
97
Zhou
,
X.
,
Liu
,
Z.
,
Zhang
,
J.
,
Adelsberger
,
J.W.
,
Yang
,
J.
and
Burton
,
G.F.
(
2016
)
Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes
.
BMC Microbiol.
16
,
172
98
Bryan
,
C.L.
,
Beard
,
K.S.
,
Pott
,
G.B.
,
Rahkola
,
J.
,
Gardner
,
E.M.
,
Janoff
,
E.N.
et al (
2010
)
HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations
.
Clin. Invest. Med.
33
,
E384
E389
99
Zhou
,
X.
,
Shapiro
,
L.
,
Fellingham
,
G.
,
Willardson
,
B.M.
and
Burton
,
G.F.
(
2011
)
HIV replication in CD4+ T lymphocytes in the presence and absence of follicular dendritic cells: inhibition of replication mediated by α-1-antitrypsin through altered IκBα ubiquitination
.
J. Immunol.
186
,
3148
3155
100
Whitney
,
J.B.
,
Asmal
,
M.
and
Geiben-Lynn
,
R.
(
2011
)
Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication
.
PLoS One
6
,
e18589
101
Shapiro
,
L.
,
Pott
,
G.B.
and
Ralston
,
A.H.
(
2001
)
Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1
.
FASEB J.
15
,
115
122
102
Pott
,
G.B.
,
Beard
,
K.S.
,
Bryan
,
C.L.
,
Merrick
,
D.T.
and
Shapiro
,
L.
(
2013
)
Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells
.
Front. Public Health
1
,
19
103
Bai
,
X.
,
Bai
,
A.
,
Honda
,
J.R.
,
Eichstaedt
,
C.
,
Musheyev
,
A.
,
Feng
,
Z.
et al (
2019
)
Alpha-1-antitrypsin enhances primary human macrophage immunity against non-tuberculous mycobacteria
.
Front. Immunol.
10
,
1417
104
Ostermann
,
L.
,
Maus
,
R.
,
Stolper
,
J.
,
Schütte
,
L.
,
Katsarou
,
K.
,
Tumpara
,
S.
et al (
2021
)
Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice
.
JCI Insight
6
,
e140816
105
Gassen
,
N.C.
,
Niemeyer
,
D.
,
Muth
,
D.
,
Corman
,
V.M.
,
Martinelli
,
S.
,
Gassen
,
A.
et al (
2019
)
SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection
.
Nat. Commun.
10
,
5770
106
Bergin
,
D.A.
,
Reeves
,
E.P.
,
Meleady
,
P.
,
Henry
,
M.
,
McElvaney
,
O.J.
,
Carroll
,
T.P.
et al (
2010
)
α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8
.
J. Clin. Invest.
120
,
4236
4250
107
Chan
,
E.D.
,
Pott
,
G.B.
,
Silkoff
,
P.E.
,
Ralston
,
A.H.
,
Bryan
,
C.L.
and
Shapiro
,
L.
(
2012
)
Alpha-1-antitrypsin inhibits nitric oxide production
.
J. Leukoc. Biol.
92
,
1251
1260
108
Jonigk
,
D.
,
Al-Omari
,
M.
,
Maegel
,
L.
,
Müller
,
M.
,
Izykowski
,
N.
,
Hong
,
J.
et al (
2013
)
Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase
.
Proc. Natl Acad. Sci. U.S.A.
110
,
15007
15012
109
Lewis
,
E.C.
(
2012
)
Expanding the clinical indications for α(1)-antitrypsin therapy
.
Mol. Med.
18
,
957
970
110
McCarthy
,
C.
,
Dunlea
,
D.M.
,
Saldova
,
R.
,
Henry
,
M.
,
Meleady
,
P.
,
McElvaney
,
O.J.
et al (
2018
)
Glycosylation repurposes alpha-1 antitrypsin for resolution of community-acquired pneumonia
.
Am. J. Respir. Crit. Care Med.
197
,
1346
1349
111
Pott
,
G.B.
,
Chan
,
E.D.
,
Dinarello
,
C.A.
and
Shapiro
,
L.
(
2009
)
Alpha-1-antitrypsin is an endogenous inhibitor of pro-inflammatory cytokine production in whole blood
.
J. Leuk. Biol.
85
,
886
895
112
Schuster
,
R.
,
Motola-Kalay
,
N.
,
Baranovski
,
B.M.
,
Bar
,
L.
,
Tov
,
N.
,
Stein
,
M.
et al (
2020
)
Distinct anti-inflammatory properties of alpha1-antitrypsin and corticosteroids reveal unique underlying mechanisms of action
.
Cell Immunol.
356
,
104177
113
Serban
,
K.A.
and
Petrache
,
I.
(
2016
)
Alpha-1 antitrypsin and lung cell apoptosis
.
Ann. Am. Thorac. Soc.
13
,
S146
S149
114
Baranovski
,
B.M.
,
Freixo-Lima
,
G.S.
,
Lewis
,
E.C.
and
Rider
,
P.
(
2015
)
T helper subsets, peripheral plasticity, and the acute phase protein, α1-antitrypsin
.
Biomed. Res. Int.
2015
,
184574
115
Shimi
,
G.
and
Zand
,
H.
(
2021
)
Association of alpha-1-antitrypsin deficiency with vitamin D status: who is most at risk of getting severe COVID-19?
Inflamm. Res.
70
,
375
377
116
Dimeloe
,
S.
,
Rice
,
L.V.
,
Chen
,
H.
,
Cheadle
,
C.
,
Raynes
,
J.
,
Pfeffer
,
P.
et al (
2019
)
Vitamin D (1,25(OH) 2D3) induces α-1-antitrypsin synthesis by CD4+ T cells, which is required for 1,25(OH) 2D3-driven IL-10
.
J. Steroid Biochem. Mol. Biol.
189
,
1
9
117
Tumpara
,
S.
,
Gründing
,
A.R.
,
Sivaraman
,
K.
,
Wrenger
,
S.
,
Olejnicka
,
B.
,
Welte
,
T.
et al (
2021
)
Boosted pro-inflammatory activity in human PBMCs by lipopolysaccharide and SARS-CoV-2 spike protein is regulated by α-1 antitrypsin
.
Int. J. Mol. Sci.
22
,
7941
118
Bai
,
X.
,
Bai
,
A.
,
Tomasicchio
,
M.
,
Hagman
,
J.R.
,
Buckle
,
A.M.
,
Gupta
,
A.
et al (
2022
)
Alpha-1-antitrypsin binds to the glucocorticoid receptor with anti-inflammatory and anti-mycobacterial significance in macrophages
.
J. Immunol.
209
,
1746
1759
119
Lu
,
Y.
,
Sun
,
K.
,
Guo
,
S.
,
Wang
,
J.
,
Li
,
A.
,
Rong
,
X.
et al (
2020
)
Early warning indicators of severe COVID-19: a single-center study of cases from Shanghai, China
.
Front. Med.
7
,
432
120
Gao
,
W.
,
Zhao
,
J.
,
Kim
,
H.
,
Xu
,
S.
,
Chen
,
M.
,
Bai
,
X.
et al (
2014
)
α1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death
.
J. Heart Lung Transplant.
33
,
309
315
121
Wang
,
X.
,
Gong
,
J.
,
Zhu
,
J.
,
Jin
,
Z.
and
Gao
,
W.
(
2019
)
Alpha 1-antitrypsin for treating ventilator-associated lung injury in acute respiratory distress syndrome rats
.
Exp. Lung Res.
45
,
209
219
122
Hogan
,
G.
,
Geoghegan
,
P.
,
Carroll
,
T.P.
,
Clarke
,
J.
,
McElvaney
,
O.F.
,
McElvaney
,
O.J.
et al (
2021
)
α1-Antitrypsin: key player or bystander in acute respiratory distress syndrome?
Anesthesiology
134
,
792
808
123
Akbasheva
,
O.E.
,
Spirina
,
L.V.
,
Dyakov
,
D.A.
and
Masunova
,
N.V.
(
2022
)
Proteolysis and deficiency of α1-proteinase inhibitor in SARS-CoV-2 infection
.
Biochem. Mosc. Suppl. B Biomed. Chem.
16
,
271
291
124
Zerimech
,
F.
,
Jourdain
,
M.
,
Onraed
,
B.
,
Bouchecareilh
,
M.
,
Sendid
,
B.
,
Duhamel
,
A.
et al (
2021
)
Protease-antiprotease imbalance in patients with severe COVID-19
.
Clin. Chem. Lab. Med.
59
,
e330
e334
125
Bigalke
,
A.
,
Neu
,
C.
,
Esper Treml
,
R.
,
Coldewey
,
S.M.
and
Kiehntopf
,
M.
(
2022
)
Fragments of alpha-1-antitrypsin in patients with severe COVID-19 and bacterial pulmonary sepsis
.
Clin. Chem. Lab. Med.
60
,
e187
e189
126
Ding
,
X.
,
Ye
,
N.
,
Qiu
,
M.
,
Guo
,
H.
,
Li
,
J.
,
Zhou
,
X.
et al (
2022
)
Cathepsin B is a potential therapeutic target for coronavirus disease 2019 patients with lung adenocarcinoma
.
Chem. Biol. Interact.
353
,
109796
127
Geraghty
,
P.
,
Rogan
,
M.P.
,
Greene
,
C.M.
,
Brantly
,
M.L.
,
O'Neill
,
S.J.
,
Taggart
,
C.C.
et al (
2008
)
Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro
.
Thorax
63
,
621
626
128
D'Avila-Mesquita
,
C.
,
Couto
,
A.E.S.
,
Campos
,
L.C.B.
,
Vasconcelos
,
T.F.
,
Michelon-Barbosa
,
J.
,
Corsi
,
C.A.C.
et al (
2021
)
MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients
.
Biomed. Pharmacother.
142
,
112067
129
da Silva-Neto
,
P.V.
,
do Valle
,
V.B.
,
Fuzo
,
C.A.
,
Fernandes
,
T.M.
,
Toro
,
D.M.
,
Fraga-Silva
,
T.F.C.
et al (
2022
)
Matrix metalloproteinases on severe COVID-19 lung disease pathogenesis: cooperative actions of MMP-8/MMP-2 axis on immune response through HLA-G shedding and oxidative stress
.
Biomolecules
12
,
604
130
Petrache
,
I.
,
Fijalkowska
,
I.
,
Medler
,
T.R.
,
Skirball
,
J.
,
Cruz
,
P.
,
Zhen
,
L.
et al (
2006
)
Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis
.
Am. J. Pathol.
169
,
1155
1166
131
Greene
,
C.M.
,
Miller
,
S.D.
,
Carroll
,
T.P.
,
Oglesby
,
I.K.
,
Ahmed
,
F.
,
O'Mahony
,
M.
et al (
2010
)
Anti-apoptotic effects of Z alpha1-antitrypsin in human bronchial epithelial cells
.
Eur. Respir. J.
35
,
1155
1163
132
Jedicke
,
N.
,
Struever
,
N.
,
Aggrawal
,
N.
,
Welte
,
T.
,
Manns
,
M.P.
,
Malek
,
N.P.
et al (
2014
)
α-1-antitrypsin inhibits acute liver failure in mice
.
Hepatology
59
,
2299
2308
133
Jiménez-Rodríguez
,
B.M.
,
Triviño-Ibáñez
,
E.M.
,
Gutiérrez-Fernández
,
J.
,
Romero-Ortiz
,
A.D.
,
Ramos-Urbina
,
E.M.
and
Morales-García
,
C.
(
2022
)
Abnormal alpha-1 antitrypsin levels and other risk factors associated with lung function impairment at 6 and 12 months after hospitalization due to COVID-19: a cohort study
.
Healthcare (Basel)
10
,
2341
134
Lascano
,
J.
,
Oshins
,
R.
,
Eagan
,
C.
,
Wadood
,
Z.
,
Qiang
,
X.
,
Flagg
,
T.
et al (
2022
)
Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection
.
PLoS One
17
,
e0274427
135
Heurich
,
A.
,
Hofmann-Winkler
,
H.
,
Gierer
,
S.
,
Liepold
,
T.
,
Jahn
,
O.
and
Pöhlmann
,
S.
(
2014
)
TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein
.
J. Virol.
88
,
1293
1307
136
Samavati
,
L.
and
Uhal
,
B.D.
(
2020
)
ACE2, much more than just a receptor for SARS-CoV-2
.
Front. Cell Infect. Microbiol.
10
,
317
137
Sodhi
,
C.P.
,
Wohlford-Lenane
,
C.
,
Yamaguchi
,
Y.
,
Prindle
,
T.
,
Fulton
,
W.B.
,
Wang
,
S.
et al (
2018
)
Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration
.
Am. J. Physiol. Lung Cell Mol. Physiol.
314
,
L17
L31
138
Zamorano Cuervo
,
N.
and
Grandvaux
,
N.
(
2020
)
ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
.
Elife
9
,
e61390
139
Bell
,
J.H.
,
Herrera
,
A.H.
,
Li
,
Y.
and
Walcheck
,
B.
(
2007
)
Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages
.
J. Leukoc. Biol.
82
,
173
176
140
Yan
,
I.
,
Schwarz
,
J.
,
Lücke
,
K.
,
Schumacher
,
N.
,
Schumacher
,
V.
,
Schmidt
,
S.
et al (
2016
)
ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses
.
J. Leukoc. Biol.
99
,
749
760
141
de Queiroz
,
T.M.
,
Lakkappa
,
N.
and
Lazartigues
,
E.
(
2020
)
ADAM17-mediated shedding of inflammatory cytokines in hypertension
.
Front. Pharmacol.
11
,
1154
142
Garton
,
K.J.
,
Gough
,
P.J.
,
Blobel
,
C.P.
,
Murphy
,
G.
,
Greaves
,
D.R.
,
Dempsey
,
P.J.
et al (
2001
)
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)
.
J. Biol. Chem.
276
,
37993
38001
143
de Loyola
,
M.B.
,
Dos Reis
,
T.T.A.
,
de Oliveira
,
G.X.L.M.
,
da Fonseca Palmeira
,
J.
,
Argañaraz
,
G.A.
and
Argañaraz
,
E.R.
(
2021
)
Alpha-1-antitrypsin: a possible host protective factor against COVID-19
.
Rev. Med. Virol.
31
,
e2157
144
Zipeto
,
D.
,
Palmeira
,
J.D.F.
,
Argañaraz
,
G.A.
and
Argañaraz
,
E.R.
(
2020
)
ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19
.
Front. Immunol.
11
,
576745
145
Li
,
X.
,
Liu
,
C.
,
Mao
,
Z.
,
Xiao
,
M.
,
Wang
,
L.
,
Qi
,
S.
et al (
2020
)
Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis
.
Crit. Care
24
,
647
146
Barnes
,
B.J.
,
Adrover
,
J.M.
,
Baxter-Stoltzfus
,
A.
,
Borczuk
,
A.
,
Cools-Lartigue
,
J.
,
Crawford
,
J.M.
et al (
2020
)
Targeting potential drivers of COVID-19: neutrophil extracellular traps
.
J. Exp. Med.
217
,
e20200652
147
Middleton
,
E.A.
,
He
,
X.-Y.
,
Denorme
,
F.
,
Campbell
,
R.A.
,
Ng
,
D.
,
Salvatore
,
S.P.
et al (
2020
)
Neutrophil extracellular traps (NETs) contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome
.
Blood
136
,
1169
1179
148
Zuo
,
Y.
,
Yalavarthi
,
S.
,
Shi
,
H.
,
Gockman
,
K.
,
Zuo
,
M.
,
Madison
,
J.A.
et al (
2020
)
Neutrophil extracellular traps in COVID-19
.
JCI Insight
5
,
e138999
149
Zuo
,
Y.
,
Yalavarthi
,
S.
,
Shi
,
H.
,
Gockman
,
K.
,
Zuo
,
M.
,
Madison
,
J.A.
et al (
2020
)
Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19
.
medRxiv
2020
,
04.09.20059626
150
Zuo
,
Y.
,
Zuo
,
M.
,
Yalavarthi
,
S.
,
Gockman
,
K.
,
Madison
,
J.A.
,
Shi
,
H.
et al (
2021
)
Neutrophil extracellular traps and thrombosis in COVID-19
.
J Thromb. Thrombolysis
51
,
446
453
151
Radermecker
,
C.
,
Detrembleur
,
N.
,
Guiot
,
J.
,
Cavalier
,
E.
,
Henket
,
M.
,
d'Emal
,
C.
et al (
2020
)
Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19
.
J. Exp. Med.
217
,
e20201012
152
Veras
,
F.P.
,
Pontelli
,
M.C.
,
Silva
,
C.M.
,
Toller-Kawahisa
,
J.E.
,
de Lima
,
M.
,
Nascimento
,
D.C.
et al (
2020
)
SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology
.
J. Exp. Med.
217
,
e20201129
153
Papayannopoulos
,
V.
,
Metzler
,
K.D.
,
Hakkim
,
A.
and
Zychlinsky
,
A.
(
2010
)
Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps
.
J. Cell Biol.
191
,
677
691
154
Silva
,
V.
and
Radic
,
M.
(
2022
)
COVID-19 pathology sheds further light on balance between neutrophil proteases and their inhibitors
.
Biomolecules
13
,
82
155
Frenzel
,
E.
,
Korenbaum
,
E.
,
Hegermann
,
J.
,
Ochs
,
M.
,
Koepke
,
J.
,
Koczulla
,
A.R.
et al (
2012
)
Does augmentation with alpha1-antitrypsin affect neutrophil extracellular traps formation?
Int. J. Biol. Sci.
8
,
1023
1025
156
D'Amato
,
M.
,
Vertui
,
V.
,
Pandolfi
,
L.
,
Bozzini
,
S.
,
Fossali
,
T.
,
Colombo
,
R.
et al (
2022
)
Investigating the link between alpha-1 antitrypsin and human neutrophil elastase in bronchoalveolar lavage fluid of COVID-19 patients
.
Curr. Issues Mol. Biol.
44
,
2122
2138
157
Lieberman
,
J.
(
2000
)
Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data
.
Chest
118
,
1480
1485
158
McElvaney
,
O.J.
,
Carroll
,
T.P.
,
Franciosi
,
A.N.
,
Sweeney
,
J.
,
Hobbs
,
B.D.
,
Kowlessar
,
V.
et al (
2020
)
Consequences of abrupt cessation of alpha1-antitrypsin replacement therapy
.
N. Engl. J. Med.
382
,
1478
1480
159
McElvaney
,
O.J.
,
O'Connor
,
E.
,
McEvoy
,
N.L.
,
Fraughan
,
D.D.
,
Clarke
,
J.
,
McElvaney
,
O.F.
et al (
2021
)
Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
.
J. Cyst. Fibros
20
,
31
35
160
Wand
,
O.
,
Dahan
,
D.
,
Tov
,
N.
,
Epstein Shochet
,
G.
,
King
,
D.A.
and
Shitrit
,
D.
(
2022
)
Intravenous alpha-1 antitrypsin therapy for critically Ill COVID-19 patients
.
Isr. Med. Assoc. J.
24
,
441
443
161
McElvaney
,
O.J.
,
McEvoy
,
N.L.
,
Boland
,
F.
,
McElvaney
,
O.F.
,
Hogan
,
G.
,
Donnelly
,
K.
et al (
2022
)
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
.
Med (N Y)
3
,
233
248
162
Strassmair
,
M.
and
Stangl
,
M.
(
2021
)
Alpha-1 antitrypsin deficiency and COVID-19 infection
.
Arch. Bronconeumol.
57
,
97
163
Gans
,
H.
and
Tan
,
B.H.
(
1967
)
α1-antitrypsin, an inhibitor for thrombin and plasmin
.
Clin. Chim. Acta
17
,
111
117
164
Clausen
,
T.M.
,
Sandoval
,
D.R.
,
Spliid
,
C.B.
,
Pihl
,
J.
,
Perrett
,
H.R.
,
Painter
,
C.D.
et al (
2020
)
SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2
.
Cell
183
,
1043
1057
165
Gozzo
,
L.
,
Viale
,
P.
,
Longo
,
L.
,
Vitale
,
D.C.
and
Drago
,
F.
(
2020
)
The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review
.
Front. Pharmacol.
11
,
1307
166
Hippensteel
,
J.A.
,
LaRiviere
,
W.B.
,
Colbert
,
J.F.
,
Langouet-Astrie
,
C.J.
and
Schmidt
,
E.P.
(
2020
)
Heparin as a therapy for COVID-19: current evidence and future possibilities
.
Am. J. Physiol. Lung Cell Mol. Physiol.
319
,
L211
L217
This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).